Reviewing TuHURA Biosciences (HURA) & Its Peers

TuHURA Biosciences (NASDAQ:HURA) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare TuHURA Biosciences to related companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, risk, profitability and earnings.

Profitability

This table compares TuHURA Biosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-248.79%	-150.83%
TuHURA Biosciences Competitors	-1,425.99%	-589.65%	-28.81%

Insider & Institutional Ownership

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares TuHURA Biosciences and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TuHURA Biosciences	N/A	-$21.68 million	-0.92
TuHURA Biosciences Competitors	$950.94 million	-$45.25 million	11.68

TuHURA Biosciences’ peers have higher revenue, but lower earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for TuHURA Biosciences and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1	0	3	2	3.00
TuHURA Biosciences Competitors	5740	12157	37591	1156	2.60

TuHURA Biosciences currently has a consensus target price of $10.33, suggesting a potential upside of 551.95%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 58.06%. Given TuHURA Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than its peers.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.